Kaiser Foundation Hospitals, operating as Kaiser Permanente, has been awarded a multiple award indefinite delivery contract by the Department of Health and Human Services Centers for Disease Control and Prevention. The 2023 Clinical Immunization Safety Assessment Base IDIQ has a potential value of $86M with a period of performance through September 2028.
Under this contract, Kaiser Permanente will support the Centers for Disease Control and Prevention's immunization safety assessment activities by facilitating epidemiological and clinical research. This includes a recent $240K delivery order to further such efforts in Oakland, California concluding in September 2028. As the prime and sole contractor without subcontractors, Kaiser Permanente will provide research services on a cost-no-fee basis.
The Clinical Immunization Safety Assessment program aims to evaluate vaccine safety through collaboration with integrated healthcare delivery organizations. This contract thus aims to procure applied epidemiological and clinical expertise to assess the safety of vaccines as administered in real-world settings. The Centers for Disease Control and Prevention oversees national vaccination programs and conducts ongoing post-licensure vaccine safety monitoring to ensure public health.
Generated 1/4/24, 9:26 PM